Key result
Transapical TAVI demonstrates ~6% 30-day mortality in severe aortic stenosis with concomitant aortic diseases.
Why the study?
Since the establishment of the transfemoral-first strategy for TAVI, an evidence gap remained regarding outcomes in patients with concomitant aortic diseases unable to undergo transfemoral access.
Does transapical TAVI provide safe mid-term outcomes in elderly patients with severe aortic stenosis and concomitant aortic diseases?
Design
Single-center observational cohort study
Follow-up
92.6 patient-years
Authors
Loading...
Transapical TAVI showed acceptable mid-term outcomes in this cohort; leaves open whether it warrants broader use when transfemoral access is infeasible.
Cohort (n=55)
No
Does transapical TAVI provide safe mid-term outcomes in elderly patients with severe aortic stenosis and concomitant aortic diseases?
Transapical TAVI is a safe and feasible alternative with promising mid-term outcomes for patients with severe aortic stenosis and concomitant aortic diseases who are unsuitable for transfemoral TAVI.
Useini et al. (2021) conducted a cohort in severe aortic stenosis and aortic diseases (n=55). Transapical transcatheter aortic valve implantation was evaluated on 30-day mortality. Transapical TAVI in patients with severe aortic stenosis and concomitant aortic diseases resulted in a 30-day mortality of 6% and a median survival time of 24.9 months (95% CI 17.6-32.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: